MRSD: a novel quantitative approach for assessing suitability of RNA-seq in the clinical investigation of mis-splicing in Mendelian disease
Authors:
- Charlie F. RowlandsCRCharlie F. Rowlands
- Nicola WhiffinNWNicola Whiffin
- Hildegard Nikki HallHHHildegard Nikki Hall
- William G. NewmanWNWilliam G. Newman
- Graeme C.M. BlackGBGraeme C.M. Black
- Raymond T. O’keefeRORaymond T. O’keefe
- Simon HubbardSHSimon Hubbard
- Diana BaralleDBDiana Baralle
- Tracy A. BriggsTBTracy A. Briggs
Preprint
Abstract
Background: RNA-sequencing of patient biosamples is a promising approach to delineate the impact of genomic variants on splicing, but variable gene expression between tissues complicates selection of appropriate tissues. Relative expression level is often used as a metric to predict RNA-sequencing utility. Here, we describe a gene- and tissue-specific metric to inform the feasibility of RNA-sequencing, overcoming some issues with using expression values alone. Results: We derive a novel metric, Minimum Required Sequencing Depth (MRSD), for all genes across three human biosamples (whole blood, lymphoblastoid cell lines (LCLs) and skeletal muscle). MRSD estimates the depth of sequencing required from RNA-sequencing to achieve user-specified sequencing coverage of a gene, transcript or group of genes of interest. MRSD predicts levels of splice junction coverage with high precision (90.1-98.2%) and overcomes transcript region-specific sequencing biases. Applying MRSD scoring to established disease gene panels shows that LCLs are the optimum source of RNA, of the three investigated biosamples, for 69.3% of gene panels. Our approach demonstrates that up to 59.4% of variants of uncertain significance in ClinVar predicted to impact splicing could be functionally assayed by RNA-sequencing in at least one of the investigated biosamples. Conclusions: We demonstrate the power of MRSD as a metric to inform choice of appropriate biosamples for the functional assessment of splicing aberrations. We apply MRSD in the context of Mendelian genetic disorders and illustrate its benefits over expression-based approaches. We anticipate that the integration of MRSD into clinical pipelines will improve variant interpretation and, ultimately, diagnostic yield.Keywords
All Related Versions
- Published version: The American Journal of Human Genetics, 109 (2), 210.
This publication has 47 references indexed in Scilit:
- Detection of aberrant splicing events in RNA-seq data using FRASERNature Communications, 2021
- Comparison of in silico strategies to prioritize rare genomic variants impacting RNA splicing for the diagnosis of genomic disorders2020
- Resolving the dark matter of ABCA4 for 1054 Stargardt disease probands through integrated genomics and transcriptomicsGenetics in Medicine, 2020
- Mapping RNA splicing variations in clinically accessible and nonaccessible tissues to facilitate Mendelian disease diagnosis using RNA-seqGenetics in Medicine, 2020
- Blood RNA analysis can increase clinical diagnostic rate and resolve variants of uncertain significanceGenetics in Medicine, 2020
- Deep-intronic ABCA4 variants explain missing heritability in Stargardt disease and allow correction of splice defects by antisense oligonucleotidesGenetics in Medicine, 2019
- Splicing mutations in human genetic disorders: examples, detection, and confirmationJournal of Applied Genetics, 2018
- Genetic diagnosis of Mendelian disorders via RNA sequencingNature Communications, 2017
- RNA mis-splicing in diseaseNature Reviews Genetics, 2015
- Evidence From Human Myectomy Samples That MYBPC3 Mutations Cause Hypertrophic Cardiomyopathy Through HaploinsufficiencyCirculation Research, 2009